IS7630A - Skiptitengdar heterósýklískar afleiður, og aðferð, gagnlegar sem virk efni gegn sykursýki og offitu - Google Patents

Skiptitengdar heterósýklískar afleiður, og aðferð, gagnlegar sem virk efni gegn sykursýki og offitu

Info

Publication number
IS7630A
IS7630A IS7630A IS7630A IS7630A IS 7630 A IS7630 A IS 7630A IS 7630 A IS7630 A IS 7630A IS 7630 A IS7630 A IS 7630A IS 7630 A IS7630 A IS 7630A
Authority
IS
Iceland
Prior art keywords
exchangeable
diabetic
obesity agent
method useful
heterocyclic derivatives
Prior art date
Application number
IS7630A
Other languages
English (en)
Inventor
T. W. Cheng Peter
Chen Sean
Devasthale Pratik
Z. Ding Charles
F. Herpin Timothy
Wu Shung
Zhang Hao
Wang Wei
Ye Xiang-Yang
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of IS7630A publication Critical patent/IS7630A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IS7630A 2002-07-09 2005-01-05 Skiptitengdar heterósýklískar afleiður, og aðferð, gagnlegar sem virk efni gegn sykursýki og offitu IS7630A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39450802P 2002-07-09 2002-07-09
PCT/US2003/022149 WO2004004665A2 (en) 2002-07-09 2003-07-02 Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method

Publications (1)

Publication Number Publication Date
IS7630A true IS7630A (is) 2005-01-05

Family

ID=30115727

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7630A IS7630A (is) 2002-07-09 2005-01-05 Skiptitengdar heterósýklískar afleiður, og aðferð, gagnlegar sem virk efni gegn sykursýki og offitu

Country Status (9)

Country Link
US (2) US7279485B2 (is)
EP (1) EP1656368A4 (is)
JP (1) JP4579681B2 (is)
AU (1) AU2003259131A1 (is)
IS (1) IS7630A (is)
NO (1) NO329938B1 (is)
PL (1) PL374860A1 (is)
TW (1) TW200422298A (is)
WO (1) WO2004004665A2 (is)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003045313A2 (en) * 2001-11-27 2003-06-05 Merck & Co. Inc. 2-aminoquinoline compounds
EP1451156A4 (en) * 2001-11-27 2005-05-25 Merck & Co Inc 4-AMINOQUINOLINE COMPOUNDS
OA12960A (en) * 2002-11-15 2006-10-13 Cadila Healthcare Ltd Substituted aralkyl derivatives.
WO2004069798A1 (ja) * 2003-02-10 2004-08-19 Banyu Pharmaceutical Co.,Ltd. ピペリジン誘導体を有効成分とするメラニン凝集ホルモン受容体拮抗剤
DE10308355A1 (de) 2003-02-27 2004-12-23 Aventis Pharma Deutschland Gmbh Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
EP1807070A1 (en) * 2004-09-29 2007-07-18 Schering Corporation Combinations of substituted azetidinones and cb1 antagonists
GB0505969D0 (en) 2005-03-23 2005-04-27 Novartis Ag Organic compounds
WO2006105127A2 (en) 2005-03-31 2006-10-05 Takeda San Diego, Inc. Hydroxysteroid dehydrogenase inhibitors
BRPI0612117A2 (pt) * 2005-06-28 2012-09-04 Merck & Co Inc composto ou um sal farmaceuticamente aceitável ou solvato do mesmo, composição farmacêutica, e, uso de um composto
MX2008002073A (es) * 2005-08-12 2008-04-16 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios.
NZ566799A (en) 2005-09-14 2011-04-29 Takeda Pharmaceutical Dipeptidyl peptidase inhibitors for treating diabetes
CN101360723A (zh) 2005-09-16 2009-02-04 武田药品工业株式会社 制备嘧啶二酮衍生物的方法
ES2430139T3 (es) 2005-12-30 2013-11-19 Novartis Ag Compuestos de piperidina 3,5-sustituido como inhibidores de renina
WO2007112347A1 (en) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
ES2541107T3 (es) 2007-06-25 2015-07-16 Novartis Ag Derivados de N5-(2-etoxietil)-N3-(2-piridinil)-3,5-piperidindicarboxamida para su uso como inhibidores de renina
CN102245570A (zh) * 2008-12-16 2011-11-16 弗·哈夫曼-拉罗切有限公司 制备吡咯烷-3-甲酸类的方法
BRPI1007414A2 (pt) * 2009-01-28 2018-03-06 Sanofi derivados de tiadiazóis e de oxadiazóis, o respectivo preparo e a respectiva aplicação em terapêutica
FR2941457A1 (fr) * 2009-01-28 2010-07-30 Sanofi Aventis Derives de thiadiazoles et d'oxadiazoles leur preparation et leur application en therapeutique
BR112012007979A2 (pt) * 2009-10-06 2016-03-29 Bristol Myers Squibb Co moduladores de gpr40 de pirrolidina
AU2011261375B2 (en) 2010-06-04 2016-09-22 Albany Molecular Research, Inc. Glycine transporter-1 inhibitors, methods of making them, and uses thereof
CN107011229B (zh) * 2012-01-06 2019-11-05 诺华股份有限公司 杂环化合物和它们的使用方法
ES2798289T3 (es) * 2012-01-25 2020-12-10 Novartis Ag Compuestos heterocíclicos y métodos para su uso
SI2920165T1 (sl) 2012-11-16 2017-02-28 Bristol-Myers Squibb Company Modulatorji dihidropirazola GPR40
US9701860B2 (en) * 2013-02-19 2017-07-11 Sun Chemical Corporation Printable radiation curable barrier coatings
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
JP2017119628A (ja) * 2014-05-09 2017-07-06 日産化学工業株式会社 置換アゾール化合物及び糖尿病治療薬
CN107677753B (zh) * 2017-11-24 2021-03-16 中山奕安泰医药科技有限公司 一种依替米贝中间体的检测方法
WO2020113094A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
CN112876427B (zh) * 2021-01-18 2022-04-22 万华化学集团股份有限公司 一种安赛蜜的制备方法
CN112679407B (zh) * 2021-03-17 2021-06-04 南京桦冠生物技术有限公司 一种手性5-取代脯氨酸类化合物的制备方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05213884A (ja) 1991-06-14 1993-08-24 Upjohn Co:The 新規な４−アミノキノリン類およびこれを有効成分とする高血圧・鬱血性心不全の予防・治療剤
GB9113628D0 (en) 1991-06-25 1991-08-14 Ici Plc Heterocyclic derivatives
US5631365A (en) * 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
WO1995018130A1 (fr) 1993-12-28 1995-07-06 Meiji Seika Kabushiki Kaisha Derives tricycliques de benzazepine et benzothiazepine
JPH08325263A (ja) 1995-05-31 1996-12-10 Sumitomo Metal Ind Ltd 新規２−アミノ−３−フェニルプロピオン酸誘導体
US6143718A (en) * 1995-06-07 2000-11-07 Amylin Pharmaceuticals, Inc. Treatment of Type II diabetes mellutis with amylin agonists
US6093714A (en) 1995-06-15 2000-07-25 Meiji Seika Kaisha, Ltd. Tricyclic benzazepine compounds
DE69728267T2 (de) 1996-02-02 2005-02-24 Merck & Co., Inc. Antidiabetisches mittel
DE69733154T2 (de) 1996-02-02 2006-03-09 Merck & Co., Inc. Verfahren zur behandlung von diabetes und verwandter krankheitszustände.
AU1856997A (en) 1996-02-02 1997-08-22 Merck & Co., Inc. Method for raising hdl cholesterol levels
WO1997028137A1 (en) 1996-02-02 1997-08-07 Merck & Co., Inc. Heterocyclic derivatives as antidiabetic and antiobesity agents
GB9604242D0 (en) 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
EP0925063A4 (en) 1996-07-01 2000-12-27 Lilly Co Eli Blood-glucose-lowering and lipid-lowering compounds
CA2259431A1 (en) 1996-07-01 1998-01-08 Eli Lilly And Company Hypoglycemic and hypolipidemic compounds
EP0948327B1 (en) 1996-12-23 2006-03-08 Merck & Co., Inc. Antidiabetic agents
AU8559598A (en) 1997-08-08 1999-03-01 Ono Pharmaceutical Co. Ltd. Gamma-type regulators for peroxisome proliferator-activated receptor
AU8750298A (en) 1997-08-28 1999-03-22 Ono Pharmaceutical Co. Ltd. Peroxisome proliferator-activated receptor controllers
WO1999015520A1 (fr) 1997-09-19 1999-04-01 Ono Pharmaceutical Co., Ltd. Composes de benzene fusionnes ou non fusionnes
ATE233764T1 (de) 1997-09-29 2003-03-15 Meiji Seika Kaisha Tricyclische triazolobenzazepinderivate, verfahren zu ihrer herstellung und antiallergische mittel
HUP0101022A1 (hu) 1997-10-17 2001-10-28 Aventis Pharmaceuticals Products Inc. Kinolinszármazékok gyógyászati alkalmazása
CN1280574A (zh) 1997-10-27 2001-01-17 雷迪研究基金会 新的杂环化合物及其在医药中的应用、它们的制备方法和含有它们的药物组合物
KR100620337B1 (ko) 1998-03-10 2006-09-13 오노 야꾸힝 고교 가부시키가이샤 카르복실산 유도체와 그 유도체를 유효 성분으로서함유하는 약제
AU1120599A (en) 1998-04-23 1999-03-08 Dr. Reddy's Research Foundation New heterocyclic compounds and their use in medicine, process for their reparation and pharmaceutical compositions containing them
HUP0102477A3 (en) * 1998-06-30 2002-08-28 Pfizer Prod Inc Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases and pharmaceutical compositions containing the compounds
GB9817118D0 (en) 1998-08-07 1998-10-07 Glaxo Group Ltd Pharmaceutical compounds
CZ20013834A3 (cs) 1999-04-28 2002-04-17 Aventis Pharma Deutschland Gmbh Deriváty kyselin se třemi arylovými zbytky jako ligandy receptorů PPAR a farmaceutické prostředky, které je obsahují
EP1177187B1 (en) 1999-04-28 2007-07-25 Sanofi-Aventis Deutschland GmbH Di-aryl acid derivatives as ppar receptor ligands
TWI260321B (en) * 1999-09-22 2006-08-21 Bristol Myers Squibb Co Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
US6414002B1 (en) * 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
PT1228067E (pt) * 1999-11-10 2004-11-30 Takeda Chemical Industries Ltd Compostos heterociclicos de cinco membros com actividade hipoglicemica e hipolipidemica
US7105556B2 (en) * 2001-05-30 2006-09-12 Bristol-Myers Squibb Company Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method
US6967212B2 (en) * 2001-05-30 2005-11-22 Bristol-Myers Squibb Company Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method

Also Published As

Publication number Publication date
WO2004004665A3 (en) 2004-03-25
WO2004004665A2 (en) 2004-01-15
PL374860A1 (en) 2005-11-14
US7951793B2 (en) 2011-05-31
TW200422298A (en) 2004-11-01
AU2003259131A1 (en) 2004-01-23
JP4579681B2 (ja) 2010-11-10
NO20050077L (no) 2005-02-03
JP2005536494A (ja) 2005-12-02
NO329938B1 (no) 2011-01-24
EP1656368A4 (en) 2009-08-26
EP1656368A2 (en) 2006-05-17
US20040063700A1 (en) 2004-04-01
US7279485B2 (en) 2007-10-09
AU2003259131A8 (en) 2004-01-23
US20070287713A1 (en) 2007-12-13

Similar Documents

Publication Publication Date Title
IS7630A (is) Skiptitengdar heterósýklískar afleiður, og aðferð, gagnlegar sem virk efni gegn sykursýki og offitu
HRP20040930A2 (en) Acyl-4-carboxyphenylurea derivatives, method for production and use thereof
GB2403245B (en) Methods and apparatus for expanding tubulars
AP2132A (en) A method of suspending, completing and working over a well
NO20040719L (no) Ekspanderende forlengelserorhenger og fremgangsmate for a sette forlengelserorhengeren
NO20041156L (no) Anordning og fremgangsmate for a sammenkople forsider av deler
NO20090890L (no) Ekspanderbart nedihullsverktøy og fremgangsmåte for ekspandering av nedihullsverktøyet
AU2003251337A8 (en) Drilling method
PL372123A1 (en) Thiazole derivatives
HK1081529A1 (en) N-acylaminobenzene derivatives as selective monoamine oxidase b inhibitors
GB0219896D0 (en) Dihydropyridine derivatives
ZA200604586B (en) Method for modifying starch or starch derivatives
NO20051875D0 (no) Kjoleror og fremgangsmate for bruk av dette
GB0417424D0 (en) Tong jaw and a method for constructing the tong jaw
HK1072747A1 (en) Printing apparatus, printing method and program
HK1075650A1 (en) Acyl-3-carboxyphenylurea derivatives, method for production and use thereof
HK1071722A1 (en) Printing apparatus, printing method, and program
AU2003275214A8 (en) Methods and apparatus for open hole drilling
AU2003230392A8 (en) Beta-secretase inhibitors
AU2003216620A8 (en) Method of stabilizing bupropion hydrochloride tablets
NO20054168D0 (no) Substituerte 3-(benzoylureido)-tiofenderivater, fremgangsmate for fremstilling og anvendelse derav
NO20043708L (no) Fremgangsmate og anording for borekaksbehandling
AU2003220391A8 (en) Reclaimer device and method thereof
GB0226609D0 (en) Heterocyclic derivatives
IS7866A (is) Nýjar píperidínafleiður og notkun þeirra sem mónóamín-taugaboðefna-endurupptökuhindrar